<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PeerJ</journal-id>
    <journal-id journal-id-type="iso-abbrev">PeerJ</journal-id>
    <journal-id journal-id-type="publisher-id">peerj</journal-id>
    <journal-id journal-id-type="pmc">peerj</journal-id>
    <journal-title-group>
      <journal-title>PeerJ</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2167-8359</issn>
    <publisher>
      <publisher-name>PeerJ Inc.</publisher-name>
      <publisher-loc>San Diego, USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6752186</article-id>
    <article-id pub-id-type="publisher-id">7414</article-id>
    <article-id pub-id-type="doi">10.7717/peerj.7414</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Bioinformatics</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Genomics</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Molecular Biology</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Engrailed 1 overexpression as a potential prognostic marker in Lower Grade Glioma</article-title>
    </title-group>
    <contrib-group>
      <contrib id="author-1" contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Jin</given-names>
        </name>
        <xref ref-type="aff" rid="aff-1">1</xref>
      </contrib>
      <contrib id="author-2" contrib-type="author" corresp="yes">
        <name>
          <surname>Zhang</surname>
          <given-names>Yu-Qi</given-names>
        </name>
        <xref ref-type="aff" rid="aff-2">2</xref>
        <email>yuqi9597@sina.com</email>
      </contrib>
      <aff id="aff-1"><label>1</label><institution>Beijing Institute of Functional Neurosurgery, Department of Functional Neurosurgery, Xuanwu Hospital, Capital Medical University</institution>, <city>Beijing</city>, <country>China</country></aff>
      <aff id="aff-2"><label>2</label><institution>Department of Neurosurgery, Yuquan Hospital, Tsinghua University</institution>, <city>Beijing</city>, <country>China</country></aff>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Orlov</surname>
          <given-names>Yuriy</given-names>
        </name>
      </contrib>
    </contrib-group>
    <pub-date pub-type="epub" date-type="pub" iso-8601-date="2019-09-16">
      <day>16</day>
      <month>9</month>
      <year iso-8601-date="2019">2019</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2019</year>
    </pub-date>
    <volume>7</volume>
    <elocation-id>e7414</elocation-id>
    <history>
      <date date-type="received" iso-8601-date="2019-03-25">
        <day>25</day>
        <month>3</month>
        <year iso-8601-date="2019">2019</year>
      </date>
      <date date-type="accepted" iso-8601-date="2019-07-04">
        <day>4</day>
        <month>7</month>
        <year iso-8601-date="2019">2019</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>©2019 Zhu and and Zhang</copyright-statement>
      <copyright-year>2019</copyright-year>
      <copyright-holder>Zhu and and Zhang</copyright-holder>
      <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="https://peerj.com/articles/7414"/>
    <abstract>
      <sec>
        <title>Background</title>
        <p>Engrailed 1 (EN1), as a member of homeobox-containing transcription factors, participates in the development of the brain. High expressions of EN1 exist in various tumors. However, the role of EN1 in lower grade glioma (LGG) is still unknown.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p>Coefficients of Cox regression were examined by data mining among 13 cancer types using OncoLnc to validate EN1 expressions in LGG patients from The Cancer Genome Atlas database (TCGA). Bioinformatic analysis was performed by using R2 and the UCSC Xena browser based on the data from 273 glioma cases in GSE16011 from GEO datasets and 530 cases of LGG patients in TCGA. Cases in GSE16011 were divided into two groups according to IDH1 mutation status. Cases in TCGA-LGG were classified to subtypes according to histopathological results, IDH1 mutation status and 1p19q status. The Kaplan–Meier survival curves were performed to analyze the relationship between EN1 expressions and clinicopathological characteristics and survival time respectively.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p>Cox regression results showed that LGG was ranked statistically first among 13 different cancer types according to the false discovery rate (FDR) correction. Results from GSE16011 showed that: glioma, LGG and LGG with IDH1 mutation patients with high EN1 expressions had significantly shorter 5, 10, and 15-year overall survival time (OS) (<italic>p</italic> &lt; 0.001). Similar results from TCGA-LGG showed that LGG patients with high EN1 expressions had significantly shorter 15-year OS, irrespective of IDH1 mutation and 1p19q co-deletion (<italic>p</italic> &lt; 0.001). The astrocytoma subgroup showed highest levels of EN1 expression and shortest 5, 10 and 15-year OS compared with oligoastrocytoma and oligodendroglioma (<italic>p</italic> &lt; 0.05).</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p>EN1 can be used as a prognostic marker in LGG patients, combined with IDH1 mutation and 1p19q co-deletion.</p>
      </sec>
    </abstract>
    <kwd-group kwd-group-type="author">
      <kwd>Engrailed 1</kwd>
      <kwd>Lower grade glioma</kwd>
      <kwd>Biomarker</kwd>
      <kwd>Oncogene</kwd>
    </kwd-group>
    <funding-group>
      <award-group id="fund-1">
        <funding-source>Beijing Postdoctoral Research Foundation</funding-source>
        <award-id> ZZ2019-15</award-id>
      </award-group>
      <funding-statement>We received financial support from the Beijing Postdoctoral Research Foundation (grant number: ZZ2019-15). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
    </funding-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro">
    <title>Introduction</title>
    <p>Gliomas are the most common primary brain tumors and can be divided into four grades based on the classification scheme of the World Health Organization (WHO). The lower grade gliomas (LGGs) constitute 20% of all gliomas, with various biological features and comparatively good prognosis (<xref rid="ref-18" ref-type="bibr">Ruiz &amp; Lesser, 2009</xref>). LGGs traditionally include WHO grade I and grade II gliomas, whose main pathological types include astrocytoma, oligoastrocytoma, oligodendroglioma and so on (<xref rid="ref-6" ref-type="bibr">Ceccarelli et al., 2016</xref>). The clinical symptoms usually present with seizures and other neurological disorders, depending on the size and location of the tumor. Although with benign pathology, LGGs may sometimes even transform to high grade gliomas (HGGs). With combined and available treatments, 10-year survival rate of patients with LGGs is still lesser than 50% (<xref rid="ref-19" ref-type="bibr">Shaw, Scheithauer &amp; O’Fallon, 1997</xref>).</p>
    <p>With the development of research on the causes and mechanism of glioma, lots of oncogenes and tumor-suppressor genes have been found. They can promote or inhibit the growth and progress of the tumor through various pathways. The genetically-targeted treatment becomes a novel method nowadays (<xref rid="ref-12" ref-type="bibr">Karsy et al., 2017</xref>). IDH1 mutation and loss of 1p/19q in LGG patients usually comply to longer overall survival (OS) (<xref rid="ref-11" ref-type="bibr">Izquierdo et al., 2018</xref>).</p>
    <p>Engrailed 1 (EN1), a neural-specific transcription factor, plays a crucial role in the development of many tissues and organs (<xref rid="ref-11" ref-type="bibr">Izquierdo et al., 2018</xref>). EN1 expression persists not only in the dopaminergic neurons of the substantia nigra but also the ventral tegmental area not just in the embryonic stage but also during the whole individual’s life (<xref rid="ref-1" ref-type="bibr">Alvarez-Fischer et al., 2011</xref>). High EN1 expression has been found in patients with breast tumors (<xref rid="ref-4" ref-type="bibr">Beltran, Graves &amp; Blancafort, 2014</xref>), salivary gland adenoid cystic carcinoma (<xref rid="ref-3" ref-type="bibr">Bell et al., 2012</xref>) and adenoid cystic carcinoma (<xref rid="ref-7" ref-type="bibr">Drier et al., 2016</xref>), with increased recurrence and mortality rate. However, the relationship between EN1 and LGGs has not been reported.</p>
    <p>In this study, by data mining in large micro-array datasets, we characterized the expression profile of EN1 in LGGs with histological subtypes, IDH1 mutation and 1p19q co-deletion status to assess the associations between EN1 expression and OS.</p>
  </sec>
  <sec>
    <title>Material and Methods</title>
    <sec>
      <title>Datasets</title>
      <p>Glioma patients were assessed with the data in GSE16011 from the GEO dataset. Of all the 284 cases in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>, 273 were glioma and 117 were LGG. 46 cases were LGG with IDH1 mutation, and 45 cases were LGG without IDH1 mutation.</p>
      <p>The LGG cohort in TCGA database (TCGA-LGG) was obtained from the UCSC Xena browser (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net">https://xenabrowser.net</ext-link>), which included 530 cases of LGG with genomic and clinical data. The genomic dataset contained IDH1 status, chromosome 1p19q deletion status, EN1 mRNA expression and so on. The clinical dataset contained demographic, survival rate, histological and pathological information.</p>
    </sec>
    <sec>
      <title>Bioinformatic analysis of the association between EN1 expression and OS in patients with glioma and LGG</title>
      <p>Coefficients of Cox regression were examined by data mining among 13 TCGA cancer types using OncoLnc (<ext-link ext-link-type="uri" xlink:href="http://112www.oncolnc.org">http://112www.oncolnc.org</ext-link>) to compare EN1 expression in different tumors (<xref ref-type="fig" rid="fig-1">Fig. 1A</xref>).</p>
      <fig id="fig-1" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.7717/peerj.7414/fig-1</object-id>
        <label>Figure 1</label>
        <caption>
          <title>Coefficients of Cox regression of EN1 in different cancers and flow-chart of research.</title>
          <p>(A) Coefficients of Cox regression were examined by data mining among 13 TCGA cancer types using OncoLnc (<ext-link ext-link-type="uri" xlink:href="http://www.oncolnc.org">http://www.oncolnc.org</ext-link>). (B) A flow-chart showed detailed information about cases in two datasets and methods of research.</p>
        </caption>
        <graphic xlink:href="peerj-07-7414-g001"/>
      </fig>
      <p>The association between EN1 expression and OS (5, 10 and 15-years) in glioma and LGG patients was assessed with data in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>. The R2 web-based application (<ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl">http://r2.amc.nl</ext-link>) was used to generate Kaplan–Meier survival curves of data in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>. Of the 273 qualified glioma cases in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>, 156 were glioblastoma multiforme (GBM), 117 were LGG. Survival data of LGG with or without IDH1 mutation was extracted for analysis. Kaplan–Meier curves of OS were generated by using the auto-select best cutoff (<xref ref-type="fig" rid="fig-1">Fig. 1B</xref>).</p>
      <p>Survival data of the LGG subgroup in the TCGA dataset was analyzed through the UCSC Xena browser. Three grouping methods were selected: histological type, IDH1 mutation and 1p19q co-deletion. Gene expression data was extracted to compare the differences in EN1 expression among different subtypes. Kaplan–Meier survival curves were generated to analyze EN1 expression and OS (<xref ref-type="fig" rid="fig-1">Fig. 1B</xref>).</p>
    </sec>
    <sec>
      <title>Statistical analysis</title>
      <p>Coefficients of Cox regression were examined using OncoLnc <italic>P</italic> values of all the cancer types and they were corrected by false-discovery rate (FDR) and FDR &lt;0.25 was considered statistically significant. Kaplan–Meier survival analysis was performed by using R2 web-based platform and the UCSC Xena browser. <italic>P</italic> &lt; 0.05 is considered statistically significant.</p>
    </sec>
  </sec>
  <sec sec-type="results">
    <title>Results</title>
    <sec>
      <title>EN1 expression in LGG is most distinct among all known tumor types</title>
      <p>Cox regression analysis was performed in the TCGA datasets. The results showed that EN1 expression in LGG was ranked statistically first among 13 different cancer types according to FDR correction (<xref ref-type="fig" rid="fig-1">Fig. 1A</xref>).</p>
    </sec>
    <sec>
      <title>High EN1 expression might be an indicator of poor OS in patients with glioma and LGG</title>
      <p>Kaplan–Meier survival analysis was chosen to explore the association between EN1 expression and 5, 10 and 15-year OS in patients with glioma through data mining in R2 using data in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri> (<xref ref-type="fig" rid="fig-2">Figs. 2A</xref>–<xref ref-type="fig" rid="fig-2">2F</xref>).</p>
      <fig id="fig-2" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.7717/peerj.7414/fig-2</object-id>
        <label>Figure 2</label>
        <caption>
          <title>Kaplan–Meier curves of OS in glioma and LGG patients with high or low EN1 expression in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>.</title>
          <p>(A–C) Kaplan-Meier curves of 5-year OS (A), 10-year OS (B) and 15-year OS (C) in the glioma patients with high or low EN1 expression in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>. (D–F) Kaplan-Meier curves of 5-year OS (D), 10-year OS (E) and 15-year OS (F) in the LGG patients with high or low EN1 expression in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>. OS curves were generated by using auto-select best cutoff. High or low EN1 expression are showed in red or blue color respectively. Analysis was performed using R2.</p>
        </caption>
        <graphic xlink:href="peerj-07-7414-g002"/>
      </fig>
      <p>Higher expression of EN1 in glioma correlated with shorter patient 5, 10 and 15-year OS according to R2 (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-2">Figs. 2A</xref>–<xref ref-type="fig" rid="fig-2">2C</xref>). LGG patients with higher expression of EN1 also had shorter 5, 10 and 15-year OS (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-2">Figs. 2D</xref>–<xref ref-type="fig" rid="fig-2">2F</xref>).</p>
    </sec>
    <sec>
      <title>High EN1 expression might be an indicator of poor OS in LGG patients with IDH1 mutation</title>
      <p>Kaplan–Meier survival analysis was chosen to explore the association between EN1 expression and 5, 10 and 15 year OS in LGG patients with/without IDH1 mutation through data mining in R2 using data in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri> (<xref ref-type="fig" rid="fig-3">Figs. 3A</xref>–<xref ref-type="fig" rid="fig-3">3F</xref>).</p>
      <fig id="fig-3" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.7717/peerj.7414/fig-3</object-id>
        <label>Figure 3</label>
        <caption>
          <title>Kaplan-Meier curves of OS in LGG patients with or without IDH1 mutation in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>.</title>
          <p>(A–C) Kaplan-Meier curves of 5-year OS (A), 10-year OS (B) and 15-year OS (C) in the LGG patients with IDH1 mutation in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>. (D–F) Kaplan-Meier curves of 5-year OS (D), 10-year OS (E) and 15-year OS (F) in the LGG patients without IDH1 mutation in GSE16011. OS curves were generated by using auto-select best cutoff. High or low EN1 expression are showed in red or blue color respectively. Analysis was performed using R2.</p>
        </caption>
        <graphic xlink:href="peerj-07-7414-g003"/>
      </fig>
      <p>Higher expression of EN1 in LGG with IDH1 mutation correlated with shorter patient 5, 10 and 15- year OS (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-3">Figs. 3A</xref>–<xref ref-type="fig" rid="fig-3">3C</xref>). It seemed that higher expression of EN1 in LGG with IDH1 mutation correlated with shorter patient 5, 10 and 15- year OS, but there was no statistical significance (<italic>p</italic> &gt; 0.05) (<xref ref-type="fig" rid="fig-3">Figs. 3D</xref>–<xref ref-type="fig" rid="fig-3">3F</xref>).</p>
    </sec>
    <sec>
      <title>EN1 expression in different histological subtypes of LGG</title>
      <p>To detect EN1 expression in different histological subtypes of LGG and association between them, we examined the expression profile of EN1 in various histological subtypes of LGG based on TCGA-LGG (<xref ref-type="fig" rid="fig-4">Fig. 4A</xref>).</p>
      <fig id="fig-4" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.7717/peerj.7414/fig-4</object-id>
        <label>Figure 4</label>
        <caption>
          <title>EN1 expression and Kaplan-Meier curves of OS in different histological subtypes in TCGA-LGG.</title>
          <p>(A–B). Heat map and the corresponding box plots of EN1 expression profile in various histological subtypes of LGG based on TCGA-LGG. (C–E). Kaplan-Meier curves of 5-year OS (C), 10-year OS (D) and 15-year OS (E) in the subtypes of LGG with high or low EN1 expression in TCGA-LGG. OS curves were generated by setting median EN1 expression as cutoff. Analysis was performed using the UCSC Xena browser.</p>
        </caption>
        <graphic xlink:href="peerj-07-7414-g004"/>
      </fig>
      <p>The box plots showed highest EN1 expression in patients with astrocytoma (<italic>p</italic> &lt; 0.001), but no statistical differences had been found between oligoastrocytoma and oligodendroglioma patients (<italic>p</italic> &gt; 0.05) (<xref ref-type="fig" rid="fig-4">Fig. 4B</xref>).</p>
      <p>Kaplan–Meier survival analysis was also generated to detect the association between 5, 10, and 15- year OS in patients with three histological subtypes. Along with EN1 expression, patients with astrocytoma had the shortest OS (<italic>p</italic> &lt; 0.05). Remarkably, oligoastrocytoma and oligodendroglioma patients had similar longer OS. These results showed that EN1 may be a prognostic maker for different histological subtypes, especially for astrocytoma (<xref ref-type="fig" rid="fig-4">Figs. 4C</xref>–<xref ref-type="fig" rid="fig-4">4E</xref>).</p>
    </sec>
    <sec>
      <title>EN1 expression in LGG patients with/without IDH1 mutation from TCGA-LGG dataset</title>
      <p>To further confirm the findings of data from the GEO dataset, we classified the cases in TCGA-LGG dataset into two groups: LGG with IDH1 mutation and LGG without IDH1 mutation. Heat map and the corresponding box plots showed that LGG with IDH1 mutation patients had a lower EN1 expression (<xref ref-type="fig" rid="fig-5">Figs. 5A</xref>–<xref ref-type="fig" rid="fig-5">5B</xref>).</p>
      <fig id="fig-5" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.7717/peerj.7414/fig-5</object-id>
        <label>Figure 5</label>
        <caption>
          <title>EN1 expression in LGG patients with or without IDH1 mutation in TCGA-LGG.</title>
          <p>(A) The heat map of EN1 expression in genomic subclassifications of LGG, including patient samples, IDH1 mutation status and EN1 mRNA expression level. (B) The corresponding box plots of EN1 expression profile in LGG patients with or without IDH1 mutation based on TCGA-LGG. (C) Kaplan-Meier curves of 15-year OS in the subtypes of LGG with or without IDH1 mutation. (D) Kaplan-Meier curves of 15-year OS in patients with high or low EN1 expression in IDH1 mutation group. (E) Kaplan-Meier curves of 15-year OS in patients with high or low EN1 expression in no IDH1 mutation group. OS curves were generated by setting median EN1 expression as cutoff. High or low EN1 expression are showed in red or blue color, respectively. Analysis was performed using the UCSC Xena browser.</p>
        </caption>
        <graphic xlink:href="peerj-07-7414-g005"/>
      </fig>
      <p>Kaplan–Meier curves was generated and showed that the LGG with IDH1 mutation had significantly more 15-year OS (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-5">Figs. 5B</xref>–<xref ref-type="fig" rid="fig-5">5C</xref>).</p>
      <p>The negative correlation between EN1 expression and OS existed in both LGG irrespective of IDH1 mutation: Lower expression of EN1 correlated with improved patient 15-year OS (<italic>p</italic> &lt; 0.05) (<xref ref-type="fig" rid="fig-5">Figs. 5D</xref>–<xref ref-type="fig" rid="fig-5">5E</xref>).</p>
    </sec>
    <sec>
      <title>EN1 expression in LGG patients irrespective of 1p19q co-deletion from TCGA-LGG dataset</title>
      <p>Based on the data of 1p19q status and EN1 expression, a heat map was generated. Heat map and the corresponding box plots showed that: LGG with 1p19q co-deletion expressed lower levels of EN1 in comparison with the no 1p19q co-deletion group (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-6">Figs. 6A</xref>–<xref ref-type="fig" rid="fig-6">6B</xref>).</p>
      <fig id="fig-6" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.7717/peerj.7414/fig-6</object-id>
        <label>Figure 6</label>
        <caption>
          <title>EN1 expression in LGG patients with or without 1p19q co-deletion in TCGA-LGG.</title>
          <p>(A) The heat map of EN1 expression in genomic subclassifications of LGG, including patient samples, 1p19q DNA copy number status and EN1 mRNA expression level. (B) The corresponding box plots of EN1 expression profile in LGG patients with or without 1p19q co-deletion based on TCGA-LGG. (C) Kaplan-Meier curves of 15-year OS in the subtypes of LGG with or without 1p19q co-deletion. (D) Kaplan-Meier curves of 15-year OS in patients with high or low EN1 expression in 1p19q co-deletion group. (E) Kaplan-Meier curves of 15-year OS in patients with high or low EN1 expression in no 1p19q co-deletion group. OS curves were generated by setting median EN1 expression as cutoff. High or low EN1 expression are showed in red or blue color, respectively. Analysis was performed using the UCSC Xena browser.</p>
        </caption>
        <graphic xlink:href="peerj-07-7414-g006"/>
      </fig>
      <p>The results of Kaplan–Meier survival analysis showed that: (1) 15- year OS in LGG patients with 1p19q co-deletion is significantly higher than the ones without 1p19q co-deletion (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-6">Fig. 6C</xref>); (2) Higher EN1 expression is consistent with shorter 15- year OS in LGG patients with/without 1p19q co-deletion (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig-6">Figs. 6D</xref>–<xref ref-type="fig" rid="fig-6">6E</xref>).</p>
    </sec>
  </sec>
  <sec>
    <title>Disscussion</title>
    <p>EN1, a murine homologue of the Drosophila homeobox gene engrailed (EN), is required for midbrain and cerebellum development and dorsal/ventral patterning of the limbs. EN1 may form a complex or directly play its role through development (<xref rid="ref-5" ref-type="bibr">Bilovocky et al., 2003</xref>). Since first reported in 1926, Drosophila, flies and other animal experiments were selected to explore its function (<xref rid="ref-10" ref-type="bibr">Higashijima et al., 2004</xref>; <xref rid="ref-8" ref-type="bibr">Frankel et al., 2010</xref>; <xref rid="ref-2" ref-type="bibr">Barolo, 2012</xref>). The results showed that EN1 mutation may reduce adrenergic and serotonergic neurons of the vertebrate brainstem (<xref rid="ref-14" ref-type="bibr">Kumar et al., 2009</xref>).</p>
    <p>Expression of EN1 can be found in lots of structures including the central nervous system (<xref rid="ref-16" ref-type="bibr">Plummer, De Marchena &amp; Jensen, 2016</xref>). In schizophrenic patients, EN1 was discovered to be associated with antipsychotic response (<xref rid="ref-20" ref-type="bibr">Webb et al., 2008</xref>). In patients with tumors, high EN1 expression was associated with reduced survival time (<xref rid="ref-20" ref-type="bibr">Webb et al., 2008</xref>). In mice with loss of EN1, Parkinson disease-like motor or non-motor symptoms will appear, which implies that EN1 probably can be a therapeutic target for Parkinson disease (<xref rid="ref-17" ref-type="bibr">Rekaik et al., 2015</xref>). EN1 may also play a critical role in the modulation of calvarial osteoblast differentiation and proliferation to ensure proper skull vault formation (<xref rid="ref-21" ref-type="bibr">Zheng et al., 2015</xref>)</p>
    <p>EN1 may promote the proliferation, migration and multinucleation of cancer cells via transcriptional activation of HDAC8, UTP11L and ZIC3 (<xref rid="ref-13" ref-type="bibr">Kim et al., 2018</xref>). The interference peptides (EN1-iPeps) that selectively inhibit EN1 activity can be used for the treatment of aggressive basal-like triple negative breast carcinomas (<xref rid="ref-9" ref-type="bibr">Gandhi, Blancafort &amp; Mancera, 2018</xref>). EN1-iPeps inhibit interactions between EN1 and its binding partners such as glutamyl-prolyl tRNA synthetase (EPRS) (<xref rid="ref-4" ref-type="bibr">Beltran, Graves &amp; Blancafort, 2014</xref>). Combined with traditional anti-tumor drugs, it has an obvious inhibitory effect.</p>
    <p>The EN1 expression in human glioma and subtypes has not been reported. We chose two online databases to analyze EN1 expressions in glioma and LGG. LGG were grouped according to histological types, IDH1 mutation status and 1p19q co-deletion status. R2 results showed that lower EN1 expression was significantly correlated with longer 5, 10 and 15-year OS in glioma and LGG patients in the GEO dataset. Kaplan–Meier survival curves were similar in LGG patients with IDH1 mutation and without mutation; although no significant difference was found in the latter group.</p>
    <p>The TCGA-LGG data analysis results were consistent with R2 results. EN1 expression in LGG was ranked statistically first among all 13 different cancer types according to the FDR correction. The astrocytoma had the highest EN1 expression and shortest OS compared to oligoastrocytoma and oligodendroglioma. Compared with the corresponding group, LGG with IDH1 mutation or 1p19q co-deletion had a lower EN1 expression and a longer OS. Whether with IDH1 mutation or not, LGG patients with lower EN1 expression had significantly more 15-year OS. The similar negative correlation existed in patients with/without 1p19q co-deletion.</p>
    <p>Therapy for LGG is a challenge for neurosurgeons. Previous studies showed that IDH1 mutation and 1p19q co-deletion may be related to the therapeutic effect in LGG patients and has been used as prognostic indicator (<xref rid="ref-15" ref-type="bibr">Mondesir et al., 2016</xref>). By data analysis in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri> and TCGA-LGG, the consistent results showed that EN1 might be an indicator of favorable OS in glioma, especially in LGG. Combined with IDH1 and 1p19q, EN1 may be used for preoperative and postoperative evaluation. If EN1 is selected as a novel gene treatment target for LGG patients, OS might be prolonged in the future.</p>
    <p>Our findings offer some evidence for EN1 effect on survival rate in LGG patients with different status. Because of limited technological methods, we cannot explore the specific carcinogenic pathway of EN1. Further studies would be necessary to elucidate the underlying mechanism of EN1.</p>
  </sec>
  <sec sec-type="conclusions">
    <title>Conclusions</title>
    <p>In conclusion, as the first research of EN1 in LGG is shown, these results support the importance and specificity of EN1 effect on survival rate in LGG patients with/without IDH1 mutation and 1p19q co-deletion. EN1 can be a potential indicator of favorable OS.</p>
  </sec>
</body>
<back>
  <sec sec-type="additional-information">
    <title>Additional Information and Declarations</title>
    <fn-group content-type="competing-interests">
      <title>Competing Interests</title>
      <fn id="conflict-1" fn-type="COI-statement">
        <p>The authors declare there are no competing interests.</p>
      </fn>
    </fn-group>
    <fn-group content-type="author-contributions">
      <title>Author Contributions</title>
      <fn id="contribution-1" fn-type="con">
        <p><xref ref-type="contrib" rid="author-1">Jin Zhu</xref> conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.</p>
      </fn>
      <fn id="contribution-2" fn-type="con">
        <p><xref ref-type="contrib" rid="author-2">Yu-Qi Zhang</xref> conceived and designed the experiments, authored or reviewed drafts of the paper, approved the final draft.</p>
      </fn>
    </fn-group>
    <fn-group content-type="other">
      <title>Data Availability</title>
      <fn id="addinfo-1">
        <p>The following information was supplied regarding data availability:</p>
        <p>The R2 web-based application (<ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl">http://r2.amc.nl</ext-link>) was used to generate Kaplan–Meier survival curves of data in <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011">GSE16011</uri>. Cox coefficients were examined by data mining among 13 TCGA cancer types using OncoLnc (<ext-link ext-link-type="uri" xlink:href="http://www.oncolnc.org/">http://www.oncolnc.org/</ext-link>) to compare EN1 expression in different tumors. LGG cohort in TCGA database (TCGA-LGG) was obtained from the UCSC Xena browser: <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/projects/TCGA-LGG">https://portal.gdc.cancer.gov/projects/TCGA-LGG</ext-link>.</p>
      </fn>
    </fn-group>
  </sec>
  <ref-list content-type="authoryear">
    <title>References</title>
    <ref id="ref-1">
      <label>Alvarez-Fischer et al. (2011)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alvarez-Fischer</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Fuchs</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Castagner</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Stettler</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Massiani-Beaudoin</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Moya</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>Bouillot</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Oertel</surname>
            <given-names>WH</given-names>
          </name>
          <name>
            <surname>Lombès</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Faigle</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Joshi</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Hartmann</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Prochiantz</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <year>2011</year>
        <article-title>Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults</article-title>
        <source>Nature Neuroscience</source>
        <volume>14</volume>
        <issue>10</issue>
        <fpage>1260</fpage>
        <lpage>1266</lpage>
        <pub-id pub-id-type="doi">10.1038/nn.2916</pub-id>
        <pub-id pub-id-type="pmid">21892157</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-2">
      <label>Barolo (2012)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barolo</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <year>2012</year>
        <article-title>Shadow enhancers: frequently asked questions about distributed cis-regulatory information and enhancer redundancy</article-title>
        <source>Bioessays</source>
        <volume>34</volume>
        <issue>2</issue>
        <fpage>135</fpage>
        <lpage>141</lpage>
        <pub-id pub-id-type="doi">10.1002/bies.201100121</pub-id>
        <pub-id pub-id-type="pmid">22083793</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-3">
      <label>Bell et al. (2012)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bell</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Weber</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>El-Naggar</surname>
            <given-names>AK</given-names>
          </name>
        </person-group>
        <year>2012</year>
        <article-title>Developmental transcription factor EN1–a novel biomarker in human salivary gland adenoid cystic carcinoma</article-title>
        <source>Cancer</source>
        <volume>118</volume>
        <issue>5</issue>
        <fpage>1288</fpage>
        <lpage>1292</lpage>
        <pub-id pub-id-type="doi">10.1002/cncr.26412</pub-id>
        <pub-id pub-id-type="pmid">21800291</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-4">
      <label>Beltran, Graves &amp; Blancafort (2014)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Beltran</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Graves</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Blancafort</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <year>2014</year>
        <article-title>Novel role of engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function</article-title>
        <source>Oncogene</source>
        <volume>33</volume>
        <issue>39</issue>
        <fpage>4767</fpage>
        <lpage>4777</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2013.422</pub-id>
        <pub-id pub-id-type="pmid">24141779</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-5">
      <label>Bilovocky et al. (2003)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bilovocky</surname>
            <given-names>NA</given-names>
          </name>
          <name>
            <surname>Romito-Digiacomo</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Murcia</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Maricich</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Herrup</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <year>2003</year>
        <article-title>Factors in the genetic background suppress the engrailed-1 cerebellar phenotype</article-title>
        <source>Journal of Neuroscience</source>
        <volume>23</volume>
        <issue>12</issue>
        <fpage>5105</fpage>
        <lpage>5112</lpage>
        <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-12-05105</pub-id>
        <pub-id pub-id-type="pmid">12832534</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-6">
      <label>Ceccarelli et al. (2016)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ceccarelli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Barthel</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Malta</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Sabedot</surname>
            <given-names>TS</given-names>
          </name>
          <name>
            <surname>Salama</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Morozova</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Newton</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Radenbaugh</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pagnotta</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Anjum</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Manyam</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Zoppoli</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ling</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Grifford</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cherniack</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Poisson</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Carlotti Jr</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Tirapelli</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mikkelsen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Yung</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Rabadan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Huse</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Brat</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Lehman</surname>
            <given-names>NL</given-names>
          </name>
          <name>
            <surname>Barnholtz-Sloan</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hess</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Meyerson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Beroukhim</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Akbani</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wrensch</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Haussler</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Aldape</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Laird</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Gutmann</surname>
            <given-names>DH</given-names>
          </name>
          <collab>TCGA Research Network</collab>
          <name>
            <surname>Noushmehr</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Iavarone</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Verhaak</surname>
            <given-names>RG</given-names>
          </name>
        </person-group>
        <year>2016</year>
        <article-title>Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma</article-title>
        <source>Cell</source>
        <volume>164</volume>
        <issue>3</issue>
        <fpage>550</fpage>
        <lpage>563</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2015.12.028</pub-id>
        <pub-id pub-id-type="pmid">26824661</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-7">
      <label>Drier et al. (2016)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Drier</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Cotton</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Williamson</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Gillespie</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Ryan</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Kluk</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Carey</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Rodig</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Sholl</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Afrogheh</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Faquin</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Queimado</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wick</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>El-Naggar</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Bradner</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Moskaluk</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Aster</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Knoechel</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Bernstein</surname>
            <given-names>BE</given-names>
          </name>
        </person-group>
        <year>2016</year>
        <article-title>An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma</article-title>
        <source>Nature Genetics</source>
        <volume>48</volume>
        <issue>3</issue>
        <fpage>265</fpage>
        <lpage>272</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3502</pub-id>
        <pub-id pub-id-type="pmid">26829750</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-8">
      <label>Frankel et al. (2010)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Frankel</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>GK</given-names>
          </name>
          <name>
            <surname>Vargas</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Payre</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Stern</surname>
            <given-names>DL</given-names>
          </name>
        </person-group>
        <year>2010</year>
        <article-title>Phenotypic robustness conferred by apparently redundant transcriptional enhancers</article-title>
        <source>Nature</source>
        <volume>466</volume>
        <issue>7305</issue>
        <fpage>490</fpage>
        <lpage>493</lpage>
        <pub-id pub-id-type="doi">10.1038/nature09158</pub-id>
        <pub-id pub-id-type="pmid">20512118</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-9">
      <label>Gandhi, Blancafort &amp; Mancera (2018)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gandhi</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Blancafort</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mancera</surname>
            <given-names>RL</given-names>
          </name>
        </person-group>
        <year>2018</year>
        <article-title>Atomistic molecular dynamics simulations of bioactive engrailed 1 interference peptides (EN1-iPeps)</article-title>
        <source>Oncotarget</source>
        <volume>9</volume>
        <issue>32</issue>
        <fpage>22383</fpage>
        <lpage>22397</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.25025</pub-id>
        <pub-id pub-id-type="pmid">29854286</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-10">
      <label>Higashijima et al. (2004)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Higashijima</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Masino</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Mandel</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Fetcho</surname>
            <given-names>JR</given-names>
          </name>
        </person-group>
        <year>2004</year>
        <article-title>Engrailed-1 expression marks a primitive class of inhibitory spinal interneuron</article-title>
        <source>Journal of Neuroscience</source>
        <volume>24</volume>
        <issue>25</issue>
        <fpage>5827</fpage>
        <lpage>5839</lpage>
        <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5342-03</pub-id>
        <pub-id pub-id-type="pmid">15215305</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-11">
      <label>Izquierdo et al. (2018)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Izquierdo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Alentorn</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Idbaih</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Simó</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kaloshi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ricard</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Barritault</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Meyronet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bruna</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Honnorat</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Delattre</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Ducray</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <year>2018</year>
        <article-title>Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics</article-title>
        <source>Journal of Neuro-Oncology</source>
        <volume>136</volume>
        <issue>3</issue>
        <fpage>533</fpage>
        <lpage>539</lpage>
        <pub-id pub-id-type="doi">10.1007/s11060-017-2677-4</pub-id>
        <pub-id pub-id-type="pmid">29143276</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-12">
      <label>Karsy et al. (2017)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karsy</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Guan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Colman</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <year>2017</year>
        <article-title>New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M</article-title>
        <source>Current Neurology and Neuroscience Reports</source>
        <volume>17</volume>
        <issue>2</issue>
        <fpage>19</fpage>
        <pub-id pub-id-type="doi">10.1007/s11910-017-0722-5</pub-id>
        <pub-id pub-id-type="pmid">28271343</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-13">
      <label>Kim et al. (2018)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>YJ</given-names>
          </name>
          <name>
            <surname>Sung</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Oh</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Vrancken</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>YL</given-names>
          </name>
        </person-group>
        <year>2018</year>
        <article-title>Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer</article-title>
        <source>Cancer Biology Therapy</source>
        <volume>19</volume>
        <issue>4</issue>
        <fpage>335</fpage>
        <lpage>345</lpage>
        <pub-id pub-id-type="doi">10.1080/15384047.2018.1423913</pub-id>
        <pub-id pub-id-type="pmid">29333926</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-14">
      <label>Kumar et al. (2009)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fung</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lichtneckert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Reichert</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hartenstein</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <year>2009</year>
        <article-title>Arborization pattern of engrailed-positive neural lineages reveal neuromere boundaries in the Drosophila brain neuropil</article-title>
        <source>Journal of Comparative Neurology</source>
        <volume>517</volume>
        <issue>1</issue>
        <fpage>87</fpage>
        <lpage>104</lpage>
        <pub-id pub-id-type="doi">10.1002/cne.22112</pub-id>
        <pub-id pub-id-type="pmid">19711412</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-15">
      <label>Mondesir et al. (2016)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mondesir</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Willekens</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Touat</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>De Botton</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <year>2016</year>
        <article-title>IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives</article-title>
        <source>Journal of Blood Medicine</source>
        <volume>7</volume>
        <fpage>171</fpage>
        <lpage>180</lpage>
        <pub-id pub-id-type="doi">10.2147/JBM.S70716</pub-id>
        <pub-id pub-id-type="pmid">27621679</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-16">
      <label>Plummer, De Marchena &amp; Jensen (2016)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Plummer</surname>
            <given-names>NW</given-names>
          </name>
          <name>
            <surname>De Marchena</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <year>2016</year>
        <article-title>A knock-in allele of En1 expressing dre recombinase</article-title>
        <source>Genesis</source>
        <volume>54</volume>
        <issue>8</issue>
        <fpage>447</fpage>
        <lpage>454</lpage>
        <pub-id pub-id-type="doi">10.1002/dvg.22954</pub-id>
        <pub-id pub-id-type="pmid">27313055</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-17">
      <label>Rekaik et al. (2015)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rekaik</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Blaudin</surname>
            <given-names>DTF</given-names>
          </name>
          <name>
            <surname>Prochiantz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fuchs</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Joshi</surname>
            <given-names>RL</given-names>
          </name>
        </person-group>
        <year>2015</year>
        <article-title>Dissecting the role of engrailed in adult dopaminergic neurons–insights into parkinson disease pathogenesis</article-title>
        <source>FEBS Letters</source>
        <volume>589</volume>
        <issue>24 Pt A</issue>
        <fpage>3786</fpage>
        <lpage>3794</lpage>
        <pub-id pub-id-type="doi">10.1016/j.febslet.2015.10.002</pub-id>
        <pub-id pub-id-type="pmid">26459030</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-18">
      <label>Ruiz &amp; Lesser (2009)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ruiz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lesser</surname>
            <given-names>GJ</given-names>
          </name>
        </person-group>
        <year>2009</year>
        <article-title>Low-grade gliomas</article-title>
        <source>Current Treatment Options in Oncology</source>
        <volume>10</volume>
        <issue>3–4</issue>
        <fpage>231</fpage>
        <lpage>242</lpage>
        <pub-id pub-id-type="doi">10.1007/s11864-009-0096-2</pub-id>
        <pub-id pub-id-type="pmid">19381819</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-19">
      <label>Shaw, Scheithauer &amp; O’Fallon (1997)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shaw</surname>
            <given-names>EG</given-names>
          </name>
          <name>
            <surname>Scheithauer</surname>
            <given-names>BW</given-names>
          </name>
          <name>
            <surname>O’Fallon</surname>
            <given-names>JR</given-names>
          </name>
        </person-group>
        <year>1997</year>
        <article-title>Supratentorial gliomas: a comparative study by grade and histologic type</article-title>
        <source>Journal of Neuro-Oncology</source>
        <volume>31</volume>
        <issue>3</issue>
        <fpage>273</fpage>
        <lpage>278</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1005715703598</pub-id>
        <pub-id pub-id-type="pmid">9049856</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-20">
      <label>Webb et al. (2008)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Webb</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Sullivan</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Skelly</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Van den Oord</surname>
            <given-names>EJ</given-names>
          </name>
        </person-group>
        <year>2008</year>
        <article-title>Model-based gene selection shows engrailed 1 is associated with antipsychotic response</article-title>
        <source>Pharmacogenetics and Genomics</source>
        <volume>18</volume>
        <issue>9</issue>
        <fpage>751</fpage>
        <lpage>759</lpage>
        <pub-id pub-id-type="doi">10.1097/FPC.0b013e32830162bc</pub-id>
        <pub-id pub-id-type="pmid">18698228</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-21">
      <label>Zheng et al. (2015)</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>HF</given-names>
          </name>
          <name>
            <surname>Forgetta</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Hsu</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Estrada</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rosello-Diez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Leo</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Dahia</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Park-Min</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Tobias</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Kooperberg</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kleinman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Styrkarsdottir</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>CT</given-names>
          </name>
          <name>
            <surname>Uggla</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Nielson</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Walter</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Pettersson-Kymmer</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Eriksson</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kwan</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Jhamai</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Trajanoska</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Memari</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Min</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Danecek</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wilmot</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Chou</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Mokry</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Moayyeri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Claussnitzer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Cheung</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Medina-Gómez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ge</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Oei</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Fraser</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kraaij</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hibbs</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Gregson</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Paquette</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hofman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wibom</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Tranah</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Marshall</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gardiner</surname>
            <given-names>BB</given-names>
          </name>
          <name>
            <surname>Cremin</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Auer</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hsu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ring</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tung</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Thorleifsson</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Enneman</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Van Schoor</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>De Groot</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Van der Velde</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Melin</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kemp</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Christiansen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sayers</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Calderari</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Van Rooij</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Carlson</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Peters</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Berlivet</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dostie</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Uitterlinden</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Farber</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Grinberg</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>LaCroix</surname>
            <given-names>AZ</given-names>
          </name>
          <name>
            <surname>Haessler</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chasman</surname>
            <given-names>DI</given-names>
          </name>
          <name>
            <surname>Giulianini</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Rose</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Ridker</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>TV</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Nogues</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Garcia-Giralt</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Launer</surname>
            <given-names>LL</given-names>
          </name>
          <name>
            <surname>Gudnason</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Mellström</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vandenput</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Amin</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Van Duijn</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Karlsson</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Ljunggren</surname>
            <given-names>ö</given-names>
          </name>
          <name>
            <surname>Svensson</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Hallmans</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rousseau</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Giroux</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bussière</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Arp</surname>
            <given-names>PP</given-names>
          </name>
          <name>
            <surname>Koromani</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Prince</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Langdahl</surname>
            <given-names>BL</given-names>
          </name>
          <name>
            <surname>Hermann</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Kaptoge</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Khaw</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Reeve</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Formosa</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Xuereb-Anastasi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Åkesson</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>McGuigan</surname>
            <given-names>FE</given-names>
          </name>
          <name>
            <surname>Garg</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Olmos</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Zarrabeitia</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Riancho</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Ralston</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Alonso</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Goltzman</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pastinen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Grundberg</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gauguier</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Orwoll</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Karasik</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Davey-Smith</surname>
            <given-names>G</given-names>
          </name>
          <collab>AOGC Consortium</collab>
          <name>
            <surname>Smith</surname>
            <given-names>AV</given-names>
          </name>
          <name>
            <surname>Siggeirsdottir</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>TB</given-names>
          </name>
          <name>
            <surname>Zillikens</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Van Meurs</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Thorsteinsdottir</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Maurano</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Timpson</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Soranzo</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Durbin</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Ntzani</surname>
            <given-names>EE</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Stefansson</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hinds</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Spector</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Cupples</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Ohlsson</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Greenwood</surname>
            <given-names>CM</given-names>
          </name>
          <collab>UKK Consortium</collab>
          <name>
            <surname>Jackson</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Rowe</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Loomis</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Ackert-Bicknell</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Joyner</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Duncan</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Kiel</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Rivadeneira</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Richards</surname>
            <given-names>JB</given-names>
          </name>
        </person-group>
        <year>2015</year>
        <article-title>Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture</article-title>
        <source>Nature</source>
        <volume>526</volume>
        <issue>7571</issue>
        <fpage>112</fpage>
        <lpage>117</lpage>
        <pub-id pub-id-type="doi">10.1038/nature14878</pub-id>
        <pub-id pub-id-type="pmid">26367794</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
